OS Therapies has reached agreement with the FDA, MHRA and EMA on an adaptive design for a Phase 3 trial of OST-HER2, a gene-edited cancer immunotherapy targeting metastatic osteosarcoma. The company plans to begin the trial in late 2026. The development expands on the program's earlier regulatory engagement, including incremental FDA alignment and the MHRA's invitation to participate in Project Orbis.